Article: Desitin to develop and sell Zogenix' sumatriptan DosePro in EU.(Desitin Pharmaceuticals GmbH)(European Union)(Brief article)

Zogenix, a privately-held US specialty drugmaker, has entered into a license agreement to grant exclusive rights in the European Union to Germany's Desitin Pharmaceuticals GmbH to develop and commercialize Zogenix' late-stage, single-use, needle-free product for migraine headache, sumatriptan DosePro. The investigational agent, which incorporates Zogenix' DosePro needle-free drug-delivery technology, has demonstrated bioequivalence to UK drug major GlaxoSmithKline's Imitrex STATdose System ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!